|Bid||0.00 x 2900|
|Ask||0.00 x 1000|
|Day's Range||87.76 - 89.63|
|52 Week Range||58.59 - 95.30|
|Beta (3Y Monthly)||1.84|
|PE Ratio (TTM)||16.27|
|Earnings Date||May 2, 2019 - May 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||97.66|
The acquisition deal between Bristol-Myers and Celgene faces opposition from stakeholders of Bristol-Myers. The future of the deal depends on the outcome of the Special Meeting in April.
Management and shareholders at Bristol-Myers Squibb continue to spar over the firm’s proposed acquisition of Celgene. Recommendations from proxy-advisory firms will be critical to whether the deal goes ahead.
Bristol-Myers Squibb and activist shareholder Starboard Value are still tussling over the looming $74 billion Celgene acquisition, but analysts are looking ahead to a key proxy vote.
ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.
In a nearly 200-page presentation calling for investors to reject Bristol-Myers Squibb’s proposed acquisition of Celgene released on Monday, activist hedge fund Starboard Value called Celgene’s pipeline of new drugs “unproven.
Puma Biotech (PBYI) gains an approval in Australia for Nerlynx as an extended adjuvant treatment in adult patients with early stage HER2-positive breast cancer.
How Major Pharmaceutical Stocks Are Positioned This Month(Continued from Prior Part)Analysts’ recommendations and target priceAnalysts expect an upside potential of 13.72% for Bristol-Myers Squibb (BMY) based on the company’s closing price on
Less than a month before shareholders vote on Bristol-Myers Squibb’s proposed take over of Celgene, activist hedge fund Starboard Value released a presentation detailing its opposition to the deal.
traded blows with activist investor Starboard Value LP Tuesday as the pair issued competing presentations linked to the pharmaceutical group's planned $74 billion takeover of cancer drug specialist Celgene Corp. Bristol Myers said the deal, which if first unveiled in early January, would mean give combined companies number one positions in oncology and cardiovascular drug sales, with a top five standing in immunology and inflammation and nine currency products with over $1 billion in sales. Starboard, for its part, opposes the deal, arguing Celgene is a company facing a "massive patent cliff" that will force it to replace some 60% of its revenues over the next seven years.
PhaseBio's (PHAS) stock skyrockets on positive data from an early-stage study evaluating PB2452, showing immediate and sustained reduction in bleeding risk in patients taking AstraZeneca's Brilinta.
The FDA approves Allergan's (AGN) sNDA for the label expansion of its antibacterial medicine, Avycaz, to treat cUTI and cIAI in pediatric patients.
Jim Cramer thinks that Bristol-Myer's deal with Celgene is a positive thing, despite Starboard's resistance.
Bristol-Myers, Tilray, and Elon Musk are some of the top headlines in business news Tuesday. Here's what Jim Cramer's watching.
posted a wider-than-expected fourth quarter loss but said sales nearly tripled in a growing global market for medical marijuana. Tilray said earnings for the three months ending in December were pegged at a net loss of 33 cents per share, compared to a 4 cents per share profit from the same period in 2017, a figure it put down to "operating expenses related to growth initiatives, expansion of international teams and costs related to financings and M&A activities." Group sales, however, rose more than 200% to $15.5 million, while total kilogram equivalents increased nearly three-fold to 2,053 and the average net selling price rose 5.5% to $7.52 per gram, reported TheStreet's Martin Baccardax. Elon Musk is still in hot water with the SEC about his Twitter presence.
Celgene Corp NASDAQ/NGS:CELGView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is extremely low for CELG with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting CELG. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding CELG are favorable, with net inflows of $11.87 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Activist investor says Bristol-Myers' Celgene deal "is ill-advised and could destroy substantial value for shareholders"; Bristol-Myers argues the deal "is a financially and strategically compelling transaction."
Bristol-Myers (BMY) and partner Pfizer ) announce results from the phase IV - AUGUSTUS study evaluating Eliquis (apixaban) versus vitamin K antagonists (VKAs).